Chimeric yellow fever virus 17D-Japanese encephalitis virus vaccine: dose-response effectiveness and extended safety testing in rhesus monkeys.
about
Japanese encephalitis-a pathological and clinical perspectiveAdvanced vaccine candidates for Lassa feverJapanese encephalitis: the virus and vaccinesVaccine-mediated immunity against dengue and the potential for long-term protection against diseaseRecombinant yellow fever viruses are effective therapeutic vaccines for treatment of murine experimental solid tumors and pulmonary metastases.Recombinant chimeric yellow fever-dengue type 2 virus is immunogenic and protective in nonhuman primatesChimeric yellow fever/dengue virus as a candidate dengue vaccine: quantitation of the dengue virus-specific CD8 T-cell responseMolecular basis for attenuation of neurovirulence of a yellow fever Virus/Japanese encephalitis virus chimera vaccine (ChimeriVax-JE).Attenuation of recombinant yellow fever 17D viruses expressing foreign protein epitopes at the surface.Construction, safety, and immunogenicity in nonhuman primates of a chimeric yellow fever-dengue virus tetravalent vaccine.Attenuation of Murray Valley encephalitis virus by site-directed mutagenesis of the hinge and putative receptor-binding regions of the envelope protein.Single mutation in the flavivirus envelope protein hinge region increases neurovirulence for mice and monkeys but decreases viscerotropism for monkeys: relevance to development and safety testing of live, attenuated vaccines.A live, attenuated recombinant West Nile virus vaccine.Stable High-Producer Cell Clone Expressing Virus-Like Particles of the Japanese Encephalitis Virus E Protein for a Second-Generation Subunit VaccineVaccine candidates for dengue virus type 1 (DEN1) generated by replacement of the structural genes of rDEN4 and rDEN4Delta30 with those of DEN1Comparative Efficacies of Three Commercially Available Vaccines against West Nile Virus (WNV) in a Short-Duration Challenge Trial Involving an Equine WNV Encephalitis ModelComparative Neuropathogenesis and Neurovirulence of Attenuated Flaviviruses in Nonhuman PrimatesFunctional assignment to JEV proteins using SVMLive Chimeric and Inactivated Japanese Encephalitis Virus Vaccines Differ in Their Cross-Protective Values against Murray Valley Encephalitis VirusNeuropathogenesis and Neurovirulence of Live Flaviviral Vaccines in MonkeysA trans-Complementing Recombination Trap Demonstrates a Low Propensity of Flaviviruses for Intermolecular RecombinationAntibody responses to Asian and American genotypes of dengue 2 virus in immunized miceEvaluation of RepliVAX WN, a single-cycle flavivirus vaccine, in a non-human primate model of West Nile virus infection.A molecularly cloned, live-attenuated japanese encephalitis vaccine SA14-14-2 virus: a conserved single amino acid in the ij Hairpin of the Viral E glycoprotein determines neurovirulence in miceSequential immunization with heterologous chimeric flaviviruses induces broad-spectrum cross-reactive CD8+ T cell responses.Phase II, randomized, double-blind, placebo-controlled, multicenter study to investigate the immunogenicity and safety of a West Nile virus vaccine in healthy adultsYellow fever: the recurring plague.ChimeriVax-West Nile virus live-attenuated vaccine: preclinical evaluation of safety, immunogenicity, and efficacy.High-throughput automated image analysis of neuroinflammation and neurodegeneration enables quantitative assessment of virus neurovirulence.Tetracycline-inducible packaging cell line for production of flavivirus replicon particlesCurrent trends in West Nile virus vaccine development.Yellow fever 17D-vectored vaccines expressing Lassa virus GP1 and GP2 glycoproteins provide protection against fatal disease in guinea pigs.Live virus vaccines based on a yellow fever vaccine backbone: standardized template with key considerations for a risk/benefit assessmentJapanese encephalitis: development of new candidate vaccines.Current use and development of vaccines for Japanese encephalitis.Single-dose vaccine against tick-borne encephalitis.Macaque models of human infectious disease.Delivery strategies for novel vaccine formulations.A review of vaccine approaches for West Nile virus.Safety and efficacy of chimeric yellow Fever-dengue virus tetravalent vaccine formulations in nonhuman primates.
P2860
Q21144539-6F9FAD7C-BA04-4AC0-8ABF-DB42E8E98F10Q26823627-339C8D72-CB64-4283-85CD-E14855E3AF74Q27010434-4F64A9FA-BD11-4133-ACD8-C91DE8C94507Q27014663-0004E48E-79D1-4625-A024-A0963CA92E01Q27469314-09AA398B-E9D1-43A6-830D-557C51968004Q27469664-5B35554F-013D-4EC0-8145-82616B2A9453Q27469691-8F170CA7-33B2-4A72-8574-B0E85B025CA1Q27469763-A847963A-B084-4644-B9DD-CC54EFD838FCQ27469842-16B8716E-0C39-4C56-B902-8698234D0775Q27469921-75211B9F-BFD7-4BEA-8707-D0AF853CEB8BQ27469932-12AB4A5C-5D92-46B9-9EAC-CDCFEC5C7A68Q27472841-3CA401E7-A429-4E4F-9D5A-6C07FC311235Q27473138-D344BBE7-5154-4A88-8CF6-8346D8DC3E88Q27477712-FF5E027E-946D-43B3-A345-5AFD356F4F99Q27478162-01CECE7B-70FA-4B8E-8A49-C0CB5CF4A104Q27484655-23167AB1-3AA5-4D7C-9486-97F948AEE88FQ27486117-647DB993-DAE4-44D2-8EB3-5AFEB6310E2FQ27487351-5EF58719-6E38-44AD-BACA-DE3762B0788FQ27487967-DC50640A-CEB7-4F06-A9B5-7EDD43D070BFQ27488399-C9C7E64F-3B7C-42E0-9A9D-9FDFB8FEE319Q27490533-F40DE8C8-908E-4366-BA86-3B3B578D9D87Q33859020-194A7F9E-8216-4015-96FD-2F737C7C58F3Q33880730-5984DA71-F6E2-4C6C-AD36-BC9B3A962DDFQ33982616-4D14D404-38E6-46E7-92EE-11F627A7A6C4Q33992835-BFCC6095-1903-4F9F-97CC-9BD2D2290CD5Q34154300-EAC97824-0D97-490F-A7F6-B757C720C7C4Q34359311-F4FED5AB-1700-4BC1-B7FF-DA8D8F3061BFQ34362322-2AF012E7-1380-46AA-ABB9-642A61C668E0Q34384833-677D5142-B181-4074-BAD3-CED3490E536FQ34552578-1F61F99E-8B7A-4FAF-B0C7-D03EAB702BB2Q34788758-F004ADAB-FA18-48E5-89AE-45AC2C50002EQ35814851-4C483FF6-5092-478D-B3BB-F200B5EC98C7Q36307457-16374E6F-2830-45A7-A856-61075129249DQ36441519-407C78EC-3585-4F39-8C06-ABE8B2BF7659Q37032646-1ED3A9BC-0BDF-4BC3-8A0B-E8D4BC71BE77Q37088625-EB63708B-FC17-47D6-8E2C-40E4DC905683Q37103536-85641991-A87F-439C-9E9D-7CC6C40F12B7Q37195521-B1646740-AF13-4086-891B-E9204E78766AQ37236968-689A5656-83F4-40AE-92FE-C2DE6148E4AFQ37423499-604E5533-9F8B-4605-81B5-AE91CEF3ECD5
P2860
Chimeric yellow fever virus 17D-Japanese encephalitis virus vaccine: dose-response effectiveness and extended safety testing in rhesus monkeys.
description
2000 nî lūn-bûn
@nan
2000 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Chimeric yellow fever virus 17 ...... fety testing in rhesus monkeys
@nl
Chimeric yellow fever virus 17 ...... ety testing in rhesus monkeys.
@ast
Chimeric yellow fever virus 17 ...... ety testing in rhesus monkeys.
@en
type
label
Chimeric yellow fever virus 17 ...... fety testing in rhesus monkeys
@nl
Chimeric yellow fever virus 17 ...... ety testing in rhesus monkeys.
@ast
Chimeric yellow fever virus 17 ...... ety testing in rhesus monkeys.
@en
prefLabel
Chimeric yellow fever virus 17 ...... fety testing in rhesus monkeys
@nl
Chimeric yellow fever virus 17 ...... ety testing in rhesus monkeys.
@ast
Chimeric yellow fever virus 17 ...... ety testing in rhesus monkeys.
@en
P2093
P2860
P50
P921
P1433
P1476
Chimeric yellow fever virus 17 ...... ety testing in rhesus monkeys.
@en
P2093
A D Barrett
I Levenbook
M Ratterree
P2860
P304
P356
10.1128/JVI.74.4.1742-1751.2000
P577
2000-02-01T00:00:00Z